NMD4C Members Receive Dr David Green Awards from Muscular Dystrophy Canada

Published: 06 May 2025

We are excited to share that several NMD4C investigators and members have been honored with a Dr David Green Award from Muscular Dystrophy Canada (MDC)! Each year MDC presents their esteemed Dr David Green Awards to groups and individuals who have shown exceptional commitment to improving the lives of Canadians affected by NMDs.

As an academic research network, we rely on the incredible team of investigators who are the driving force behind our work and are thrilled to see several NMD4C investigators and patient partners who receive individual awards recognizing their contributions to the neuromuscular community! Congratulations to Margo Thompson, Dr Reshma Amin, Dr Maryam Oskoui, and Dr Marianne Nury who each received a Dr David Green Award:

  • Margo Thompson, recipient of the Leadership in Advocacy Award
  • Dr Reshma Amin, recipient of the 2025 Dr George Karpati Award for Researcher of the Year
  • Dr Maryam Oskoui, recipient of the Outstanding Healthcare Partner Award
  • Dr Marianne Nury, recipient of the Rising Clinician/Researcher Award

Read the full news release from MDC to see the full list of award winners!

David Green awards from MDC

Read next...

Hope On The Horizon: Trials Treatments and Therapies for DMD, DM1 and MG

Hope on the Horizon: Trials, Treatments and Therapies for DMD, DM1 & MG

Nov 25-28, 2025 | Join us at Hope on the Horizon to learn more about the treatment and clinical trial landscape for Duchenne Muscular Dystrophy, Myotonic Dystrophy Type 1 and Myasthenia Gravis from key experts in the field!

Website - 2026 NMD4C Awards Now Open

2026 Awards Now Open for Nominations!

We’re proud to recognize outstanding achievements across the neuromuscular research community with our Three awards: Publication of the Year, Early Career Biomedical/Clinical Researchers of the Year.

AGAMREE (vamorolone) Approved treatment for DMD in Canada

A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada

Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.